1682-1683 / 2605
Prostate:
RTOG-0938.
Phase II trial with hypofractionated RT for favorable risk prostate cancer. It
randomized between 7.25 Gy in 5 fractions versus 4.3 Gy in 12 fractions. Stage T1-T2 disease.
Study closed – reached accrual. Thus far, although protons were allowed, (almost) no proton
patients entered.
Currently, no specific concepts within RTOG’s prostate trials that would allow protons or are
proton specific..
Liver:
RTOG-1112
, open and permitting protons. Randomized phase III study of Sorafenib alone
versus SBRT followed by Sorafenib in hepatocellular CA. Intention is to give 50 Gy in 5
fractions. Total dose prescription dependent on the mean liver dose tolerance. Prescription dose
to be lowered until a level that permits mean liver dose OAR to be met. Open
Concept: RTOG-1212
, phase II-III trial of RT for liver-confined unresectable
cholangiocarcinoma randomizing induction chemotherapy followed by either more
chemotherapy plus RT versus chemotherapy alone (gemcitabine and cisplatinum x4). Will
permit protons, but still in the stage of “developing trials.” Possible opening in 2015 (?).
NRG:
NRG:
Average ,me ‘from concept to opening”: 3.5 years
Predictable what can be expected from NRG within next 5 years.
However: Increasingly Protons will be “permiFed” as RT modality in new trials –
an important step towards acceptance of p ot s as non-experimental modality.